Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.36Last Year’s EPS
-0.28Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 1.69%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and market interest for Fractyl's products, with rapid enrollment and promising initial results. However, financial challenges such as increased net loss and limited cash runway pose concerns.Company Guidance
During the call, Fractyl Health provided guidance for 2025, highlighting key metrics and milestones. The company completed full enrollment of the REMAIN-1 Pivotal Cohort ahead of schedule, targeting weight maintenance after GLP-1 drug discontinuation. They anticipate completing randomization of 315 participants in the first half of 2026 and reporting pivotal six-month primary endpoint data in the second half. The REMAIN-1 Midpoint Cohort, with 45 participants, is expected to deliver blinded controlled data in Q3 2025. In their Reveal-1 Cohort, initial results showed a 1.2% average weight regain post-GLP-1 cessation, compared to the typical 3%. Financially, Fractyl reported a net loss of $23.7 million for Q1 2025, with $42.1 million in cash and equivalents, projected to fund operations into Q4 2025. The company also made advancements with their Rejuva platform, aiming for a first-in-human study and regulatory submissions in 2026.Rapid Enrollment for REMAIN-1 Study
Completed full enrollment for the REMAIN-1 Pivotal Cohort ahead of schedule, demonstrating significant unmet need and product market fit for Revita in weight maintenance.
Encouraging Initial Results from Reveal-1 Cohort
Initial results showed an average weight regain of just 1.2% compared to the 3% typically seen after GLP-1 cessation, with persistent weight loss for some participants.
Progress in Rejuva Gene Therapy Platform
Achieved regulatory alignment with European authorities on the first-in-human study design for RJVA-001, with plans to submit the first CTA module in June.
Strong Interest in Revita from Patients and Physicians
Market research indicated strong patient interest in Revita as an alternative to chronic pharmacotherapy, highlighting a significant market opportunity.
Advancements in Manufacturing for Rejuva
Developed a large-scale CGMP manufacturing process, achieving strong, durable GLP-1 expression with a single, low-dose, and no safety signals observed.
GUTS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GUTS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $1.77 | $1.54 | -12.99% |
Mar 03, 2025 | $1.56 | $1.50 | -3.85% |
Nov 12, 2024 | $2.43 | $2.37 | -2.47% |
Aug 14, 2024 | $2.23 | $2.35 | +5.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Fractyl Health, Inc. (GUTS) report earnings?
Fractyl Health, Inc. (GUTS) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Fractyl Health, Inc. (GUTS) earnings time?
Fractyl Health, Inc. (GUTS) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GUTS EPS forecast?
GUTS EPS forecast for the fiscal quarter 2025 (Q2) is -0.36.